CapsoVision, Inc. (NASDAQ:CV – Get Free Report) major shareholder Ching Hang Shen acquired 878,734 shares of the business’s stock in a transaction that occurred on Tuesday, September 15th. The shares were acquired at an average cost of $5.69 per share, with a total value of $4,999,996.46. Following the transaction, the insider directly owned 2,926,655 shares in the company, valued at $16,652,666.95. The trade was a 42.91% increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Large shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.
CapsoVision Trading Up 5.8%
Shares of CV stock opened at $6.70 on Friday. The firm’s fifty day simple moving average is $6.41 and its 200 day simple moving average is $6.53. CapsoVision, Inc. has a 1 year low of $4.34 and a 1 year high of $15.37. The firm has a market capitalization of $335.33 million, a P/E ratio of -14.26 and a beta of -2.47.
CapsoVision (NASDAQ:CV – Get Free Report) last released its earnings results on Thursday, August 13th. The company reported ($0.15) earnings per share for the quarter. CapsoVision had a negative net margin of 214.74% and a negative return on equity of 177.85%. The company had revenue of $3.64 million during the quarter. Equities research analysts anticipate that CapsoVision, Inc. will post -0.56 EPS for the current fiscal year.
Hedge Funds Weigh In On CapsoVision
Wall Street Analysts Forecast Growth
Several analysts recently commented on the company. Benchmark reaffirmed a “speculative buy” rating on shares of CapsoVision in a research note on Friday, August 14th. Roth Capital started coverage on shares of CapsoVision in a research note on Friday, August 28th. They set a “buy” rating and a $9.00 price target on the stock. Zacks Research upgraded shares of CapsoVision to a “hold” rating in a research report on Monday, August 31st. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of CapsoVision in a research report on Monday, June 29th. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $9.50.
Check Out Our Latest Research Report on CapsoVision
CapsoVision Company Profile
CapsoVision, Inc is a medical technology company focused on developing and commercializing capsule endoscopy systems for gastrointestinal (GI) diagnostics. Its products are designed to help physicians examine the digestive tract, particularly the small intestine, using an ingestible capsule rather than a conventional endoscopic procedure.
The company’s principal product is CapsoCam Plus, an ingestible capsule endoscope that captures panoramic images as it travels through the gastrointestinal tract.
Recommended Stories
- Five stocks we like better than CapsoVision
- J.B. Hunt’s Stock Plunges After Market Misprices Profit Warning
- 2 Stocks Breaking Out Post-FOMC With One Thing in Common
- Lennar’s Q3 Miss Hides a Stronger Operating Story Beneath the Housing Slump
- These 3 Stocks Are Drawing Insider Buyers for Very Different Reasons
Receive News & Ratings for CapsoVision Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CapsoVision and related companies with MarketBeat.com's FREE daily email newsletter.
